{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:48:11Z","timestamp":1777384091122,"version":"3.51.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-148922"],"award-info":[{"award-number":["PJT-148922"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009271","name":"Canadian Nurses Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25-DA033756"],"award-info":[{"award-number":["R25-DA033756"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Equity Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The advent of highly tolerable and efficacious direct-acting antiviral (DAA) medications has transformed the hepatitis C virus (HCV) treatment landscape. Yet, people who inject drugs (PWID) \u2013 a population with inequitably high rates of HCV and who face significant socio-structural barriers to healthcare access \u2013 continue to have disproportionately low rates of DAA uptake. The objective of this study is to explore how PWID with lived experience of HCV perceive and experience DAA treatment, in a setting with universal coverage of these medications since 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Informed by a critical interpretive framework, we thematically analyze data from in-depth, semi-structured interviews conducted between January and June 2018 in Vancouver, Canada, with a purposive sample (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956) of PWID at various stages (e.g., pre, peri, post) of DAA treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis yielded three key themes: (i) life with HCV, (ii) experiences with and perceptions of evolving HCV treatments, and (iii) substance use and the uptake of DAA treatments. First, participants described how health and healthcare conditions, such as the deprioritizing of HCV (e.g., due to: being asymptomatic, healthcare provider inaction, gatekeeping) and catalysts to care (e.g., symptom onset, treatment for co-morbidities) shaped DAA treatment motivation and access. Second, participants described how individual and community-level accounts of evolving HCV treatments, including skepticism following negative experiences with Interferon-based treatment and uncertainty regarding treatment eligibility, negatively influenced willingness and opportunities to access DAAs. Concurrently, participants described how peer and community endorsement of DAAs was positively associated with treatment uptake. Third, participants favoured HCV care that was grounded in harm reduction, which included the integration of DAAs with other substance use-related services (e.g., opioid agonist therapy, HIV care), and which was often contrasted against abstinence-focused care wherein substance use is framed as a contraindication to HCV treatment access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings underscore several equity-oriented healthcare service delivery and clinician adaptations that are required to scale up DAAs among PWID living with HCV, including the provision of harm reduction-focused, non-stigmatizing, integrated, and peer-led care that responds to power differentials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12939-021-01420-7","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T09:03:48Z","timestamp":1616144628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["\u201cI want to get better, but\u2026\u201d: identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments"],"prefix":"10.1186","volume":"20","author":[{"given":"Trevor","family":"Goodyear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette J.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hoong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianping","family":"Ti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"1420_CR1","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018."},{"issue":"2","key":"1420_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: A systematic review. Ann Intern Med. 2013;158(2):114.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1420_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jvh.12684","volume":"24","author":"NZ Janjua","year":"2017","unstructured":"Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, et al. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. J Viral Hepatitis. 2017;24(8):624\u201330.","journal-title":"J Viral Hepatitis"},{"issue":"suppl_2","key":"1420_CR4","doi-asserted-by":"publisher","first-page":"80-S9","DOI":"10.1093\/cid\/cit306","volume":"57","author":"EJ Aspinall","year":"2013","unstructured":"Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clin Infect Dis. 2013;57(suppl_2):80-S9.","journal-title":"Clin Infect Dis"},{"key":"1420_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","volume":"12","author":"NZ Janjua","year":"2016","unstructured":"Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016;12:189\u201395.","journal-title":"EBioMedicine"},{"issue":"10178","key":"1420_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","volume":"393","author":"A Heffernan","year":"2019","unstructured":"Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. The Lancet. 2019;393(10178):1319\u201329.","journal-title":"The Lancet"},{"issue":"11","key":"1420_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.drugpo.2015.05.004","volume":"26","author":"N Ford","year":"2015","unstructured":"Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, et al. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. Int J Drug Policy. 2015;26(11):1088\u201393.","journal-title":"Int J Drug Policy"},{"key":"1420_CR8","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021: Towards ending viral hepatitis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: Towards ending viral hepatitis. Geneva: World Health Organization; 2016."},{"key":"1420_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugpo.2019.04.001","volume":"72","author":"SB H\u00f8j","year":"2019","unstructured":"H\u00f8j SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. The International journal of drug policy. 2019;72:11\u201323.","journal-title":"The International journal of drug policy"},{"issue":"3","key":"1420_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.17269\/s41997-018-0164-0","volume":"110","author":"R Knight","year":"2019","unstructured":"Knight R, Ti L. The successful scale-up of direct-acting antiviral hepatitis C treatments will benefit from concerted investments in implementation science. Can J Public Health. 2019;110(3):376\u20139.","journal-title":"Can J Public Health"},{"issue":"1","key":"1420_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150\u201366.","journal-title":"Addiction"},{"issue":"6","key":"1420_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","volume":"4","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study. The Lancet Gastroenterology Hepatology. 2019;4(6):435\u201344.","journal-title":"The Lancet Gastroenterology Hepatology"},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2018.06.002","volume":"59","author":"K Bird","year":"2018","unstructured":"Bird K, Soc\u00edas ME, Ti L. Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy. Int J Drug Policy. 2018;59:1\u20132.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"1420_CR14","doi-asserted-by":"publisher","first-page":"e1192-e207","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. The Lancet Global Health. 2017;5(12):e1192-e207.","journal-title":"The Lancet Global Health"},{"issue":"9","key":"1420_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/hiv.12501","volume":"18","author":"ME Soc\u00edas","year":"2017","unstructured":"Soc\u00edas ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, et al. High prevalence of willingness to use direct-acting antiviral\u2010based regimens for hepatitis C virus (HCV) infection among HIV\/HCV coinfected people who use drugs. HIV Med. 2017;18(9):647\u201354.","journal-title":"HIV Med"},{"key":"1420_CR16","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. 2017."},{"issue":"11","key":"1420_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14745\/ccdr.v42i03a02","volume":"42","author":"S Ha","year":"2016","unstructured":"Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Comm Dis Rep. 2016;42(11):57\u201362.","journal-title":"Can Comm Dis Rep"},{"issue":"9","key":"1420_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepatitis. 2019;26(9):1094\u2013104.","journal-title":"J Viral Hepatitis"},{"key":"1420_CR19","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","volume":"206","author":"AD Marshall","year":"2020","unstructured":"Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists\u2014The practitioner experience. Drug Alcohol Depend. 2020;206:107705.","journal-title":"Drug Alcohol Depend"},{"key":"1420_CR20","doi-asserted-by":"publisher","first-page":"102766","DOI":"10.1016\/j.drugpo.2020.102766","volume":"81","author":"T Goodyear","year":"2020","unstructured":"Goodyear T, Ti L, Carrieri P, Small W, Knight R. \u201cEverybody living with a chronic disease is entitled to be cured\u201d: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81:102766.","journal-title":"Int J Drug Policy"},{"key":"1420_CR21","doi-asserted-by":"crossref","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u2018Hep C\u2019s like the common cold\u2019: Understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","DOI":"10.1016\/j.drugalcdep.2018.06.013"},{"issue":"5","key":"1420_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1363459314555237","volume":"19","author":"JA Clark","year":"2015","unstructured":"Clark JA, Gifford AL. Resolute efforts to cure hepatitis C: Understanding patients\u2019 reasons for completing antiviral treatment. Health. 2015;19(5):473\u201389.","journal-title":"Health"},{"issue":"7","key":"1420_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/1467-9566.12018","volume":"35","author":"T Rhodes","year":"2013","unstructured":"Rhodes T, Harris M, Martin A. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. Sociol Health Illn. 2013;35(7):1023\u201344.","journal-title":"Sociol Health Illn"},{"issue":"1","key":"1420_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-7517-10-10","volume":"10","author":"AE Jordan","year":"2013","unstructured":"Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, et al. Perceptions of drug users regarding hepatitis C screening and care: A qualitative study. Harm reduction journal. 2013;10(1):10-.","journal-title":"Harm reduction journal"},{"issue":"11","key":"1420_CR25","doi-asserted-by":"publisher","first-page":"e0207226","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PloS one. 2018;13(11):e0207226.","journal-title":"PloS one"},{"key":"1420_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.drugpo.2019.08.003","volume":"74","author":"ME Pearce","year":"2019","unstructured":"Pearce ME, Jongbloed K, Demerais L, MacDonald H, Christian WM, Sharma R, et al. \u201cAnother thing to live for\u201d: Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. Int J Drug Policy. 2019;74:52\u201361.","journal-title":"Int J Drug Policy"},{"key":"1420_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, et al. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. Int J Drug Policy. 2017;47:26\u201333.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1420_CR28","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/MEG.0000000000000961","volume":"29","author":"OT Sims","year":"2017","unstructured":"Sims OT, Guo Y, Shoreibah MG, Venkata K, Fitzmorris P, Kommineni V, et al. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: A retrospective study in a large urban tertiary center. Eur J Gastroenterol Hepatol. 2017;29(11):1219\u201322.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"1420_CR29","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","volume":"51","author":"AK Asher","year":"2016","unstructured":"Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inect drugs. Subst Use Misuse. 2016;51(9):1218\u201323.","journal-title":"Subst Use Misuse"},{"key":"1420_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugpo.2017.02.006","volume":"47","author":"A Mah","year":"2017","unstructured":"Mah A, Hull MW, DeBeck K, Milloy MJ, Dobrer S, Nosova E, et al. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals. Int J Drug Policy. 2017;47:137\u201343.","journal-title":"Int J Drug Policy"},{"key":"1420_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4324\/9780203069097-2","volume-title":"Philosophies and practices of emancipatory nursing: Social justice as praxis 1ed","author":"AJ Browne","year":"2014","unstructured":"Browne AJ, Reimer-Kirkham S. Problematizing social justice discourses in nursing. In: Varcoe C, Browne AJ, Cender LM, editors. Philosophies and practices of emancipatory nursing: Social justice as praxis 1ed. New York: Routledge; 2014. pp.\u00a021\u201338."},{"key":"1420_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4324\/9780203069097-20","volume-title":"Philosophies and practices of emancipatory nursing: Social justice as praxis","author":"C Varcoe","year":"2014","unstructured":"Varcoe C, Browne AJ, Cender L. Promoting social justice and equity by practicing nursing to address structural inequities and structural violence. In: Kagan P, Smith M, Chinn P, editors. Philosophies and practices of emancipatory nursing: Social justice as praxis. New York: Routledge; 2014. pp.\u00a0266\u201384."},{"issue":"1","key":"1420_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12939-018-0820-2","volume":"17","author":"AJ Browne","year":"2018","unstructured":"Browne AJ, Varcoe C, Ford-Gilboe M, Nadine Wathen C, Smye V, Jackson BE, et al. Disruption as opportunity: Impacts of an organizational health equity intervention in primary care clinics. Int J Equity Health. 2018;17(1):154\u201316.","journal-title":"Int J Equity Health"},{"key":"1420_CR34","volume-title":"Constructing grounded theory","author":"K Charmaz","year":"2014","unstructured":"Charmaz K. Constructing grounded theory. 2 ed. Thousand Oaks: Sage; 2014.","edition":"2"},{"key":"1420_CR35","first-page":"181","volume-title":"Data analysis and representation. Qualitative inquiry and research design: Choosing among five approaches","author":"JW Creswell","year":"2018","unstructured":"Creswell JW, Poth CN. Data analysis and representation. Qualitative inquiry and research design: Choosing among five approaches. 4 ed. Thousand Oaks: SAGE Publicatoins, Inc.; 2018. pp.\u00a0181\u2013224.","edition":"4"},{"key":"1420_CR36","unstructured":"Statistics Canada. Population and dwelling count highlight tables: 2016 Census: Statistics Canada; 2016 [updated 2019-02-20. Available from: cfm?Lang=Eng&T=701&SR=1&S=3&O=D&RPP=9999&PR=59."},{"key":"1420_CR37","unstructured":"Lazatin LS. B.C. expands drug coverage to anyone suffering from chronic hepatitis C. 2018 March 13."},{"issue":"12","key":"1420_CR38","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/liv.14227","volume":"39","author":"SR Bartlett","year":"2019","unstructured":"Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Liver International. 2019;39(12):2261\u201372.","journal-title":"Liver International"},{"key":"1420_CR39","unstructured":"Truth and Reconciliation Commission of Canada. Honouring the truth, reconciling for the future: Summary of the final report of the Truth and Reconciliation Commission of Canada. Winnipeg: Book, Whole; 2014. Report No : 145941067X;1459410688;9781459410688$49781459410671; Contract No."},{"key":"1420_CR40","unstructured":"National Inquiry into Missing and Murdered Indigenous Women and Girls. Reclaiming power and place: Final report of the National Inquiry into Missing and Murdered Indigenous Women and Girls: Privy Council Office U6; 2019."},{"key":"1420_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.socscimed.2017.04.045","volume":"184","author":"AJ Browne","year":"2017","unstructured":"Browne AJ. Moving beyond description: Closing the health equity gap by redressing racism impacting Indigenous populations. Soc Sci Med. 2017;184:23\u20136.","journal-title":"Soc Sci Med"},{"key":"1420_CR42","volume-title":"Determinants of Indigenous peoples\u2019 health: Beyond the social","author":"M Greenwood","year":"2018","unstructured":"Greenwood M, De Leeuw S, Lindsay NM. Determinants of Indigenous peoples\u2019 health: Beyond the social. Second ed. Toronto: Canadian Scholars; 2018.","edition":"Second"},{"key":"1420_CR43","doi-asserted-by":"crossref","unstructured":"Marshall SG. Canadian drug policy and the reproduction of Indigenous inequities. International Indigenous Policy Journal. 2015;6(1).","DOI":"10.18584\/iipj.2015.6.1.7"},{"issue":"2","key":"1420_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11469-009-9225-1","volume":"8","author":"S de Leeuw","year":"2010","unstructured":"de Leeuw S, Greenwood M, Cameron E. Deviant constructions: How governments preserve colonial narratives of addictions and poor mental health to intervene into the lives of Indigenous children and families in Canada. International Journal of Mental Health Addiction. 2010;8(2):282\u201395.","journal-title":"International Journal of Mental Health Addiction"},{"key":"1420_CR45","unstructured":"Boucher R, King A, Lavand D, Nicholson V, Ryan C, Denys RS, et al. Policy brief: Indigenous harm reduction = reducing harms of colonialism. 2019."},{"issue":"4","key":"1420_CR46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s40429-016-0116-9","volume":"3","author":"HA McKenzie","year":"2016","unstructured":"McKenzie HA, Dell CA, Fornssler B. Understanding addictions among Indigenous people through social determinants of health frameworks and strength-based approaches: A review of the research lterature from 2013 to 2016. Current Addiction Reports. 2016;3(4):378\u201386.","journal-title":"Current Addiction Reports"},{"key":"1420_CR47","doi-asserted-by":"crossref","unstructured":"Skinner S, Cote G, Khan I. Hepatitis C virus infection in Saskatchewan First Nations communities: Challenges and innovations. Canada communicable disease report = Releve des maladies transmissibles au Canada. 2018;44(7\u20138):173\u20138.","DOI":"10.14745\/ccdr.v44i78a04"},{"issue":"11","key":"1420_CR48","first-page":"e488-e94","volume":"63","author":"J Gordon","year":"2017","unstructured":"Gordon J, Bocking N, Pouteau K, Farrell T, Ryan G, Kelly L. First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario. Canadian family physician Medecin de famille canadien. 2017;63(11):e488-e94.","journal-title":"Canadian family physician Medecin de famille canadien"},{"key":"1420_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drugpo.2018.08.012","volume":"65","author":"R Nitulescu","year":"2019","unstructured":"Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, et al. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy. 2019;65:41\u20139.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1420_CR50","doi-asserted-by":"publisher","first-page":"e25013","DOI":"10.1002\/jia2.25013","volume":"20","author":"S Saeed","year":"2017","unstructured":"Saeed S, Strumpf EC, Moodie EEM, Young J, Nitulescu R, Cox J, et al. Disparities in direct acting antivirals uptake in HIV-hepatitis C co\u2010infected populations in Canada. J Int AIDS Soc. 2017;20(3):e25013. .","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"1420_CR51","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/v4123912","volume":"4","author":"JD Rempel","year":"2012","unstructured":"Rempel JD, Uhanova J. Hepatitis C virus in American Indian\/Alaskan Native and Aboriginal peoples of North America. Viruses. 2012;4(12):3912\u201331.","journal-title":"Viruses"},{"key":"1420_CR52","doi-asserted-by":"crossref","unstructured":"Jongbloed K, Pearce ME, Pooyak S, Zamar D, Thomas V, Demerais L, et al. The Cedar Project: Mortality among young Indigenous people who use drugs in British Columbia. CMAJ: Canadian Medical Association journal = journal de l\u2019Association medicale canadienne. 2017;189(44):E1352-E9.","DOI":"10.1503\/cmaj.160778"},{"issue":"5","key":"1420_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533\u201344.","journal-title":"Adm Policy Ment Health"},{"key":"1420_CR54","doi-asserted-by":"publisher","first-page":"102692","DOI":"10.1016\/j.drugpo.2020.102692","volume":"78","author":"MC Kennedy","year":"2020","unstructured":"Kennedy MC, Hayashi K, Milloy MJ, Boyd J, Wood E, Kerr T. Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: A gender-based analysis. Int J Drug Policy. 2020;78:102692.","journal-title":"Int J Drug Policy"},{"key":"1420_CR55","unstructured":"British Columbia Centre for Excellence in HIV\/AIDS. Per-SVR 2020 [Available from: ."},{"issue":"2","key":"1420_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1891\/CRNR-D-19-00091","volume":"26","author":"L Carrier","year":"2020","unstructured":"Carrier L, Dame J, Lane J. Two-Spirit identity and Indigenous conceptualization of gender and sexuality: Implications for nursing practice. Creative Nursing. 2020;26(2):96\u2013100.","journal-title":"Creative Nursing"},{"issue":"10","key":"1420_CR57","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.drugpo.2015.07.002","volume":"26","author":"AD Marshall","year":"2015","unstructured":"Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy. 2015;26(10):984\u201391.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1420_CR58","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12913-016-1707-9","volume":"16","author":"AJ Browne","year":"2016","unstructured":"Browne AJ, Varcoe C, Lavoie J, Smye V, Wong ST, Krause M, et al. Enhancing health care equity with Indigenous populations: evidence-based strategies from an ethnographic study. BMC Health Serv Res. 2016;16(1):544.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"1420_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugpo.2008.02.009","volume":"19","author":"B Pauly","year":"2008","unstructured":"Pauly B. Shifting moral values to enhance access to health care: Harm reduction as a context for ethical nursing practice. Int J Drug Policy. 2008;19(3):195\u2013204.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1420_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3138\/canlivj.2018-0012","volume":"1","author":"J Chan","year":"2018","unstructured":"Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. Canadian Liver Journal. 2018;1(4):231\u20139.","journal-title":"Canadian Liver Journal"},{"issue":"1","key":"1420_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2015\/692408","volume":"29","author":"RP Myers","year":"2015","unstructured":"Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Canadian Journal of Gastroenterology Hepatology. 2015;29(1):19\u201334.","journal-title":"Canadian Journal of Gastroenterology Hepatology"},{"issue":"1","key":"1420_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12954-018-0269-z","volume":"15","author":"D Crowley","year":"2018","unstructured":"Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners\u2019 perspective. Harm Reduct J. 2018;15(1):62.","journal-title":"Harm Reduct J"},{"key":"1420_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","volume":"83","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T, Martin A. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Soc Sci Med. 2013;83:19\u201326.","journal-title":"Soc Sci Med"},{"issue":"6","key":"1420_CR64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.drugpo.2007.09.001","volume":"19","author":"J Neale","year":"2008","unstructured":"Neale J. Homelessness, drug use and hepatitis C: A complex problem explored within the context of social exclusion. Int J Drug Policy. 2008;19(6):429\u201335.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1420_CR65","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/add.13783","volume":"112","author":"J Stone","year":"2017","unstructured":"Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302\u201314.","journal-title":"Addiction"},{"issue":"2","key":"1420_CR66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3122\/jabfm.2018.02.170220","volume":"31","author":"A Simha","year":"2018","unstructured":"Simha A, Maria Webb C, Prasad R, Kolb NR, Veldkamp PJ. Moral distress with obstacles to hepatitis C treatment: A Council of Academic Family Medicine Educational Research Alliance (CERA) study of family medicine program directors. J Am Board Fam Med. 2018;31(2):286\u201391.","journal-title":"J Am Board Fam Med"},{"issue":"5","key":"1420_CR67","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","volume":"69","author":"C Rossi","year":"2018","unstructured":"Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1007\u201314.","journal-title":"J Hepatol"},{"issue":"1","key":"1420_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugalcdep.2009.06.016","volume":"105","author":"L Brener","year":"2009","unstructured":"Brener L, Resnick I, Ellard J, Treloar C, Bryant J. Exploring the role of consumer participation in drug treatment. Drug Alcohol Depend. 2009;105(1):172\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1420_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal. 2013;10(1):1\u201311.","journal-title":"Harm Reduction Journal"},{"key":"1420_CR70","unstructured":"Canadian Nurses Association. Code of ethics for registered nurses. Ottawa, ON; 2017. Report No.: 9781551194417$4."},{"key":"1420_CR71","unstructured":"Canadian Medical Association. CMA code of ethics and professionalism. 2018."},{"issue":"1","key":"1420_CR72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/14461242.2015.1126187","volume":"25","author":"C Treloar","year":"2016","unstructured":"Treloar C, Jackson LC, Gray R, Newland J, Wilson H, Saunders V, et al. Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C. Health Sociology Review. 2016;25(1):18\u201332.","journal-title":"Health Sociology Review"},{"issue":"2","key":"1420_CR73","doi-asserted-by":"publisher","first-page":"205510291560158","DOI":"10.1177\/2055102915601581","volume":"2","author":"L Brener","year":"2015","unstructured":"Brener L, Wilson H, Jackson LC, Johnson P, Saunders V, Treloar C. The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis. Health psychology open. 2015;2(2):2055102915601581.","journal-title":"Health psychology open"},{"issue":"S1","key":"1420_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/1753-6405.12402","volume":"40","author":"L Brener","year":"2016","unstructured":"Brener L, Wilson H, Jackson LC, Johnson P, Saunders V, Treloar C. Experiences of diagnosis, care and treatment among Aboriginal people living with hepatitis C. Aust N Z J Public Health. 2016;40(S1):59\u201364.","journal-title":"Aust N Z J Public Health"},{"key":"1420_CR75","volume-title":"Addressing stigma: Towards a more inclusive health system. The Chief Public Health Officer\u2019s report on the state of public health in Canada 2019","author":"Public Health Agency of Canada","year":"2019","unstructured":"Public Health Agency of Canada. Addressing stigma: Towards a more inclusive health system. The Chief Public Health Officer\u2019s report on the state of public health in Canada 2019. Ottawa: Public Health Agency of Canada; 2019."},{"issue":"suppl_4","key":"1420_CR76","doi-asserted-by":"publisher","first-page":"iv27","DOI":"10.1093\/heapol\/czw169","volume":"32","author":"FLH Chuah","year":"2017","unstructured":"Chuah FLH, Haldane VE, Cervero-Liceras F, Ong SE, Sigfrid LA, Murphy G, et al. Interventions and approaches to integrating HIV and mental health services: a systematic review. Health Policy Plan. 2017;32(suppl_4):iv27\u201347.","journal-title":"Health Policy Plan"},{"issue":"5","key":"1420_CR77","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/hep.29308","volume":"66","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Sutcliffe C, Moon J, Chander G, Wansom T, Keruly J, et al. High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. Hepatology. 2017;66(5):1402\u201312.","journal-title":"Hepatology"},{"key":"1420_CR78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","volume":"75","author":"JL Butner","year":"2017","unstructured":"Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abuse Treat. 2017;75:49\u201353.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"1420_CR79","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/add.14128","volume":"113","author":"S Christensen","year":"2018","unstructured":"Christensen S, Buggisch P, Mauss S, Boker KHW, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction. 2018;113(5):868\u201382.","journal-title":"Addiction"},{"key":"1420_CR80","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.drugpo.2017.05.021","volume":"47","author":"D Panagiotoglou","year":"2017","unstructured":"Panagiotoglou D, Krebs E, Min JE, Olding M, Ahamad K, Ti L, et al. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV? Int J Drug Policy. 2017;47:169\u201376.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1420_CR81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12879-017-2256-5","volume":"17","author":"A Cousien","year":"2017","unstructured":"Cousien A, Leclerc P, Morissette C, Bruneau J, Roy E, Tran VC, et al. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montreal, Canada: a modelling study. BMC Infect Dis. 2017;17(1):162.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"1420_CR82","doi-asserted-by":"publisher","first-page":"897","DOI":"10.7326\/M16-2887","volume":"166","author":"AH Talal","year":"2017","unstructured":"Talal AH, Thomas DL, Reynolds JL, Khalsa JH. Toward optimal control of hepatitis C virus infection in persons with substance use disorders. Ann Intern Med. 2017;166(12):897\u20138.","journal-title":"Ann Intern Med"},{"key":"1420_CR83","doi-asserted-by":"publisher","first-page":"102714","DOI":"10.1016\/j.drugpo.2020.102714","volume":"78","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Sacamano P, McCormick SD, Yang C, Kirk G, Thomas D, et al. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Int J Drug Policy. 2020;78:102714.","journal-title":"Int J Drug Policy"},{"key":"1420_CR84","doi-asserted-by":"crossref","unstructured":"Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, et al. Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. Journal of viral hepatitis. 2020.","DOI":"10.1111\/jvh.13274"},{"key":"1420_CR85","doi-asserted-by":"crossref","unstructured":"Jacob J, Ti L, Knight R. Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs? Canadian Journal of Public Health. 2020.","DOI":"10.17269\/s41997-020-00413-3"}],"container-title":["International Journal for Equity in Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-021-01420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12939-021-01420-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-021-01420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T12:16:47Z","timestamp":1616156207000},"score":1,"resource":{"primary":{"URL":"https:\/\/equityhealthj.biomedcentral.com\/articles\/10.1186\/s12939-021-01420-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1186\/s12939-021-01420-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-97222\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-97222\/v1","asserted-by":"object"}]},"ISSN":["1475-9276"],"issn-type":[{"value":"1475-9276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was obtained from the University of British Columbia Behavioural Research Ethics Board (#H16-02943). Participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}